PMGC Holdings (ELAB) Net Margin (2022 - 2026)
PMGC Holdings (ELAB) posted Net Margin of 2.86% for Q1 2026, down 59.99% sequentially from 7.15% in Q4 2025, and up 2100.0% YoY from 0.13% in Q1 2025.
PMGC Holdings (ELAB) Net Margin (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Net Margin for 5 years, with the latest figure at 2.86% in Q1 2026.
- Quarterly Net Margin rose 2100.0% year-over-year to 2.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.29% (up 7629.0% YoY) and the FY2025 annual result came in at 5.58%, up 9592.0% from the prior year.
- Net Margin eased to 2.86% in Q1 2026 per ELAB's latest filing, from 7.15% in the prior quarter.
- Over five years, Net Margin peaked at 182.86% in Q4 2022 and troughed at 449375.88% in Q4 2023.
- A 5-year average of 35678.38% and a median of 82.69% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2024: Net Margin tumbled 44955874 bps in 2023, then soared 44934575 bps in 2024.
- Over 5 years, Net Margin stood at 182.86% in 2022, then slumped by 245851 bps to 449375.88% in 2023, then surged by 100 bps to 30.14% in 2024, then jumped by 124 bps to 7.15% in 2025, then plunged by 60 bps to 2.86% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 2.86%, 7.15%, and 7.59% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 12.09% |
| 10 | PMGC Holdings | 30.04 Mn | 11.25 Mn | 385,691.00 | -329.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.86% |
| Dec 31, 2025 | 7.15% |
| Sep 30, 2025 | 7.59% |
| Mar 31, 2025 | -18.14% |
| Dec 31, 2024 | -30.14% |
| Sep 30, 2024 | -56.76% |
| Jun 30, 2024 | -141.95% |
| Mar 31, 2024 | -304.61% |
| Dec 31, 2023 | -449,375.88% |
| Sep 30, 2023 | -48,736.78% |
| Jun 30, 2023 | -334.06% |
| Mar 31, 2023 | -590.90% |
| Dec 31, 2022 | 182.86% |
| Sep 30, 2022 | -108.61% |